2 days Ago By ABMN Staff
Fresenius Medical Care AG ( NYSE:FMS – Free Report ) – Equities researchers at Zacks Research raised their Q4 2026 EPS estimates for shares of Fresenius Medical Care in a note issued to investors on Monday, December 30th. Zacks Research analyst I. Bandyopadhyay now forecasts that the company will earn $0.
62 per share for the quarter, up from their prior forecast of $0.61. The consensus estimate for Fresenius Medical Care’s current full-year earnings is $1.
55 per share. Several other equities analysts have also issued reports on FMS. Berenberg Bank initiated coverage on shares of Fresenius Medical Care in a report on Wednesday, November 6th.
They set a “buy” rating and a $25.60 target price for the company. StockNews.
com started coverage on Fresenius Medical Care in a report on Thursday, November 28th. They issued a “strong-buy” rating on the stock. Truist Financial raised their price target on Fresenius Medical Care from $22.
00 to $23.00 and gave the company a “hold” rating in a report on Monday, October 7th. Finally, Bank of America upgraded shares of Fresenius Medical Care from an “underperform” rating to a “neutral” rating in a research note on Monday, December 2nd.
One research analyst has rated the stock with a sell rating, two have given a hold rating, one has issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $24.30.
Fresenius Medical Care Trading Down 0.3 % Shares of NYSE FMS opened at $22.64 on Thursday.
The stock has a market cap of $13.29 billion, a P/E ratio of 18.71, a price-to-earnings-growth ratio of 0.
96 and a beta of 0.93. The company has a debt-to-equity ratio of 0.
42, a current ratio of 1.37 and a quick ratio of 1.02.
Fresenius Medical Care has a 1 year low of $17.93 and a 1 year high of $24.31.
The firm has a 50-day moving average of $22.19 and a 200 day moving average of $20.63.
Hedge Funds Weigh In On Fresenius Medical Care A number of institutional investors and hedge funds have recently modified their holdings of FMS. Creative Planning raised its position in Fresenius Medical Care by 18.9% in the second quarter.
Creative Planning now owns 40,140 shares of the company’s stock worth $766,000 after acquiring an additional 6,373 shares during the period. Verition Fund Management LLC purchased a new position in Fresenius Medical Care during the third quarter valued at $237,000. Wulff Hansen & CO.
grew its holdings in Fresenius Medical Care by 1,809.0% during the second quarter. Wulff Hansen & CO.
now owns 343,429 shares of the company’s stock valued at $6,556,000 after purchasing an additional 325,439 shares during the period. Charles Schwab Investment Management Inc. increased its position in Fresenius Medical Care by 11.
2% in the third quarter. Charles Schwab Investment Management Inc. now owns 22,161 shares of the company’s stock worth $472,000 after buying an additional 2,233 shares in the last quarter.
Finally, Quantinno Capital Management LP raised its stake in shares of Fresenius Medical Care by 78.9% in the third quarter. Quantinno Capital Management LP now owns 110,078 shares of the company’s stock worth $2,345,000 after buying an additional 48,554 shares during the period.
8.37% of the stock is currently owned by hedge funds and other institutional investors. Fresenius Medical Care Company Profile ( Get Free Report ) Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally.
The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient's residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. Featured Stories Receive News & Ratings for Fresenius Medical Care Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fresenius Medical Care and related companies with MarketBeat.com's FREE daily email newsletter .
.
